Medicxi Ventures Management (Jersey) Ltd
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed January 23, 2026), Medicxi Ventures Management (Jersey) Ltd reported 5 stock positions worth $835.0 million. Its top holding was Centessa Pharmaceuticals (CNTA) at 59.8% of the portfolio, followed by Phathom Pharmaceuticals (PHAT, 14.8%) and Newamsterdam Pharma (NAMS, 12.1%). Its holdings were unchanged from Q3 2025.
- Most Recent 13F
- Q2 2026
- Location
- ST. HELIER, Y9
- CIK
- 0001715579
- Portfolio Value
- $835.0M (Q4 2025)
- SEC Filing
- 0001193125-26-020931 ↗ filed Jan 23, 2026
Holdings Value
Holdings 5 stocks · $835.0M
| CNTA Centessa Pharmaceuticals Ltd. | 59.80% | 19,963,157 | $499.3M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 14.83% | 7,464,572 | $123.8M | No change |
| NAMS Newamsterdam Pharma Co. NV | 12.06% | 2,869,565 | $100.7M | No change |
| RAPT THERAPEUTICS INC | 11.33% | 2,794,000 | $94.6M | No change |
| AURA Aura Biosciences Inc. | 1.98% | 3,039,892 | $16.6M | No change |
Portfolio Sells Q3 2025 → Q4 2025
| None this quarter. | |||
Portfolio Buys Q3 2025 → Q4 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 3 | $177.4M | PHAT, NAMS, AURA |
| Q1 2026 | 4 | $981.8M | CNTA, NAMS, PHAT, AURA |
| Q4 2025 | 5 | $835.0M | CNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA |
| Q3 2025 | 5 | $744.4M | CNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA |
| Q2 2025 | 5 | $427.3M | CNTA, PHAT, NAMS, RAPT, AURA |
| Q1 2025 | 5 | $437.7M | CNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA |
| Q4 2024 | 5 | $529.0M | CNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA |
| Q3 2024 | 4 | $528.9M | CNTA, PHAT, NAMS, AURA |
| Q2 2024 | 4 | $335.3M | CNTA, PHAT, NAMS, AURA |
| Q1 2024 | 5 | $449.2M | CNTA, PHAT, NAMS, MRUS, AURA |